中國生物製藥(01177.HK)前三季基本純利升15.7%至26億元 派息每股2港仙
格隆匯11月26日丨中國生物製藥(01177.HK)公佈,截至2019年9月30日止9個月,公司實現收入約人民幣193.21億元(單位下同),同比增長約22.8%;歸屬於母公司持有者應占盈利約22.56億元,同比增長約2.5%;每股基本盈利約17.92分,派季度股息每股2港仙,前三季度合計派6港仙。
公告稱,撇除因收購北京泰德24%權益而新增可識別無形資產攤銷費用,以及扣除權益投資及金融資產的未實現公允價值利潤及虧損的影響後,歸屬於母公司持有者應占基本盈利約26.00億元,同比增長約15.7%。
集團在製藥業務方面繼續以發展專科治療領域相關產品為主,致力打造專科品牌。集團以具規模的肝病用藥系列及心腦血管用藥系列為基礎,積極拓展抗腫瘤用藥、呼吸系統用藥、鎮痛用藥、骨科用藥、消化系統科用藥、抗感染用藥、腸外營養用藥及糖尿病用藥等產品。
報告期內,肝病用藥銷售額約49.66億元,佔集團收入25.7%;抗腫瘤用藥銷售額約42.02億元,佔集團收入約21.8%;心腦血管用藥銷售額約24.95億元,佔集團收入約12.9%。;鎮痛用藥銷售額約16.53億元,佔集團收入約8.6%;骨科用藥銷售額約14.06億元,佔集團收入約7.3%,消化系統用藥銷售額約11.94億元,佔集團收入6.2%。
研發方面,集團繼續專注肝病、抗腫瘤、呼吸系統、鎮痛和心腦血管等治療領域的新產品研發。於第三季度內,集團獲得臨牀批件5件、生產批件8件及一致性評價獲批6個、申報臨牀5件、一致性評價申報8個及申報生產4個。已累計有臨牀批件、正在進行臨牀試驗和申報生產的在研產品共471件,其中肝病用藥32件、抗腫瘤用藥199件、呼吸系統用藥27件、內分泌用藥26件、心腦血管用藥47件及其它類用藥140件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.